Johnson & Johnson (JNJ)
| Market Cap | 384.45B |
| Revenue (ttm) | 88.82B |
| Net Income (ttm) | 14.07B |
| Shares Out | 2.41B |
| EPS (ttm) | 5.79 |
| PE Ratio | 27.58 |
| Forward PE | 15.11 |
| Dividend | $4.96 (3.11%) |
| Ex-Dividend Date | Feb 18, 2025 |
| Volume | 7,065,577 |
| Open | 157.15 |
| Previous Close | 157.89 |
| Day's Range | 156.95 - 159.94 |
| 52-Week Range | 140.68 - 168.85 |
| Beta | 0.51 |
| Analysts | Buy |
| Price Target | 169.76 (+6.31%) |
| Earnings Date | Apr 15, 2025 |
About JNJ
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizo... [Read more]
Financial Performance
In 2024, Johnson & Johnson's revenue was $88.82 billion, an increase of 4.30% compared to the previous year's $85.16 billion. Earnings were $14.07 billion, a decrease of -59.99%.
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price forecast is $169.76, which is an increase of 6.31% from the latest price.
News
AbbVie Vs. Johnson & Johnson: Graham Would Prefer The Consumer Healthcare Giant
Since my last analyses on JNJ and ABBV, both have released Q4 earnings. Overall, JNJ showed more pronounced unevenness in its Q4 results, while ABBV's growth story is pretty clear-cut. The goal of thi...
Fast Money: CELH, SLV, EEM, JNJ
The final trades of the day with CNBC's Dominic Chu and the Fast Money traders.
J&J begins crucial battle over $10 billion baby powder settlement
Johnson & Johnson faces a critical test on Tuesday over its $10 billion proposal to end litigation alleging that its baby powder caused ovarian cancer, as it tries to convince a judge to sign off on i...
Genmab: Positive 2025 Outlook, Johnson & Johnson's Decision Coming Soon
Genmab reported strong Q4 2024 results, with $897.4 million in revenue, beating expectations and showing 29% Y/Y growth, driven by Darzalex royalties. 2025 revenue guidance was slightly ahead of conse...
Johnson & Johnson: Rich History Of Excellence Poised To Endure
Johnson & Johnson offers a compelling balance of growth, innovation, and shareholder returns. JNJ's robust financials, including a fortress-like balance sheet and consistent dividends, support its abi...
J&J resumes US rollout of Varipulse heart device after investigation
Johnson & Johnson said on Friday it has resumed the limited market release of its Varipulse heart device in the United States after an investigation found the devices operate as intended.
Johnson & Johnson halts late-stage E.coli vaccine trial after poor results
Johnson & Johnson and Sanofi said that while the vaccine showed no safety concerns, it did not meet the necessary effectiveness thresholds.
New nipocalimab data published in mAbs journal details differentiated molecular design, clinical profile and potential of nipocalimab to treat IgG-driven alloantibody and autoantibody diseases
SPRING HOUSE, Pa., Feb. 13, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the publication of data detailing the differentiated molecular properties of nipocalimab, an investigatio...
J&J to discontinue E.coli vaccine candidate study
Johnson & Johnson said on Thursday it will discontinue a late-stage study of an experimental E.coli vaccine it was developing in partnership with Sanofi.
One 'Safer' Buy In 10 February Dogs Of The Dow
Verizon is the only Dow Dog meeting the ideal of dividends from $1K invested exceeding single share price, supported by adequate free cash flow. Analysts project net gains of 15.23% to 33.94% for the ...
3 Ideal Buys In 63 January Fortune 500 Industry Leaders Wherein 57 Paid Dividends And 39 Tested As 'Safer'
The June/July 2024 Fortune Magazine revealed 500 biggest U.S. companies by revenue and profits. Arnold-research focused on January industry-leaders using YCharts 1/30/25 data for profits from 63. Thos...
My Top 5 Dividend-Paying Buy-And-Hold Stocks For 2025
With both The Dividend Income Accelerator Portfolio and my personal investment portfolio I am following a buy-and-hold approach. While my private portfolio focuses on dividend growth, The Dividend Inc...
DCLA's Sarat Sethi on his top stock picks: JNJ, WDAY, TMO
Sarat Sethi, DCLA managing partner, joins 'Squawk Box' to discuss the latest market trends, his top stock picks, and more.
Johnson & Johnson to Participate in the 45th Annual TD Cowen Healthcare Conference
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the 45th Annual TD Cowen Healthcare Conference on Tuesday, March 4th, 2025. Management will participate in a firesid...
You Deserve Reliable Income: 2 Undervalued Dividends For Long-Term Growth
A buy-and-hold strategy is ideal for investors seeking durable companies with strong dividends and attractive valuations, avoiding tax inefficiencies from frequent trading. UPS offers a 5.7% dividend ...
US government could seek over $1 billion from J&J for cancer treatment costs
The U.S. Department of Health & Human Services may seek over $1 billion from Johnson & Johnson as reimbursement for federal health agencies' payments of medical costs for patients who allege that the ...
Why Johnson & Johnson's Strong Buy Rating Is Justified (Rating Upgrade)
On January 22, Johnson & Johnson released financial results for the fourth quarter of 2024, which beat my expectations again. So, sales of its oncology franchise reached $5.5 billion, an increase of 1...
Best 5 dividend aristocrat stocks to buy and hold
Dividend aristocrats, or companies that have paid and raised dividends for at least 25 years are some of the best value stocks to buy and hold. Many of them have solid balance sheets and a long record...
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Johnson & Johnson (JNJ) and Encourages Shareholders to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / January 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Johnson & Johnson ("J&J" or "the Company") (NYSE:JNJ...
What's Next For JNJ Stock After An Upbeat Q4?
Johnson & Johnson (NYSE: JNJ) recently reported its Q4 results, with revenues and earnings exceeding the street estimates. The company reported revenue of $22.5 billion and adjusted earnings of $2.04 ...
Johnson & Johnson's MedTech Momentum Expected To Rebound In 2025 Despite Current Hurdles: Analyst
On Wednesday, Johnson & Johnson JNJ reported a fourth-quarter adjusted EPS of $2.04, down 10.9% year over year, beating the consensus of $2.01.
Johnson & Johnson (JNJ) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Johnson & Johnson ("J&J" or "the Company") (NYSE:JNJ). Investors who purchased J&J securities are encour...
Findings from pivotal nipocalimab Phase 3 study in a broad antibody positive population of people living with generalized myasthenia gravis (gMG) published in The Lancet Neurology
The first FcRn blocker to demonstrate sustained disease control over 24 weeks in antibody positive adult patients: anti-AChR+, anti-MuSK+, anti-LRP4+ Nipocalimab demonstrated a sustained reduction in ...
Johnson & Johnson ketamine-derived nasal spray gets FDA approval for depression, but JNJ stock dips on earnings
On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson's nasal spray, Spravato (esketamine), to treat major depressive disorder.